Opdivo for non-small lung cancer – pro
Patients with advanced non-small cell lung cancer (NSCLC) who
have disease progression after first-line systemic therapy can be treated
with nivolumab, a fully human IgG4 programmed death-1 immunecheckpoint-inhibitor
antibody. In two randomized phase III trials
performed in well-selected patients, a superior overall survival and
tolerance was shown as compared to docetaxel, which was the standard
second line treatment.
OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO.
Kurt G. Tournoy et al, Does nivolumab for progressed metastatic lung cancer fulfill its promises?
An efficacy and safety analysis in 20 general hospitals. Lung cacner 115)2018), 49-55
OPdivo, Prescribing information 2018